IP Library Granted Patent US 10,441,556
Granted Patent B2
US 10,441,556 · App. 15/989,738 · Granted Oct 15, 2019

Composition containing glibenclamide

Inventors: Sven Martin Jacobson (New York, NY); Robert Ang (Cupertino, CA)
Assignee: Biogen Chesapeake LLC
A61K31/18A61K31/155A61K31/175A61K31/64A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,441,556
App. No.
15/989,738
Granted
Oct 15, 2019
Kind
B2
Abstract

NSC antagonists are disclosed as useful in the treatment of dementia, in delaying the onset of dementia, and in the prevention of dementia. Dementia so treated may be, for example, Alzheimer's Disease (AD). NSC antagonists for treating dementia such as AD may be administered alone, a) in combination with other drugs used for treating dementia, b) in combination with drugs that stabilize or increase blood plasma glucose levels, or with both a) and b). Pharmaceutical compositions, dosage forms, and methods for using the same are disclosed, which include NSC antagonists, NSC antagonists combined with dementia drugs, NSC antagonists combined with glucose-level stabilizing or enhancing drugs, or combinations of these. Dosage forms may be designed to provide stable plasma levels for extended periods of time. Exemplary pharmaceutical compositions include compositions including glibenclamide and memantine; glibenclamide and donepezil; tolbutamide and memantine; tolbutamide and donepezil; and these compositions further including glucagon and/or glucose.

Claims (11)

1. A composition suitable for intravenous administration comprising glibenclamide or a pharmaceutically acceptable salt thereof, mannitol, and a pharmaceutically acceptable carrier.

2. The composition of claim 1 , further comprising a compound effective to increase blood plasma glucose levels.

3. The composition of claim 2 , wherein said compound is glucose or glucagon.

4. The composition of claim 1 , further comprising dextrose.

5. The composition of claim 1 , wherein said composition is a single dose composition containing from 0.1 to 15 mg glibenclamide or a pharmaceutically acceptable salt thereof.

6. The composition of claim 1 , wherein said composition is a single dose composition containing from 0.1 to 5 mg glibenclamide or a pharmaceutically acceptable salt thereof.

7. The composition of claim 1 , wherein said composition is a single dose composition containing from 0.1 to 1 mg glibenclamide or a pharmaceutically acceptable salt thereof.

8. The composition of claim 1 , further comprising NaCl.

9. The composition of claim 1 , further comprising KCl.

10. The composition of claim 1 , further comprising CaCl 2 .

11. The composition of claim 1 , further comprising lactate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2023
From: BIOGEN CHESAPEAKE LLC
To: REMEDY PHARMACEUTICALS, INC.
Reel/Frame 064678/0502 →
Continuity (4)
Division 13779511 · Feb 27, 2013
Continuation 12444908
Provisional Application 60851412 · Oct 12, 2006
Related Publication 20180271811A1 · Sep 27, 2018
Cited By (3)
US 12,397,038 US 12,448,419 US 12,496,306